Elastase is not sufficient to induce experimental abdominal aortic aneurysms  by Carsten, Christopher G. et al.
more) of elastase to consistently produce AAAs in this
model.4,6,7 In our own laboratory we have noted signifi-
cant lot-to-lot variation in AAA development from differ-
ent commercial elastase preparations, and some elastase
lots failed to produce AAAs at standard doses.
Subsequently, a letter to the editor11 indicating differences
between elastase lots by protein gel electrophoresis was
published as a warning to investigators.
To clarify the discrepancies in AAA formation in the
rat elastase infusion model and to assist future investiga-
tions, we undertook this study. We evaluated aneurysm
formation by several commercial elastase preparations and
investigated their elastolytic activity and purity. Aortic
diameter was also compared with elastin degradation and
inflammation in the aorta.
METHODS
Animal surgery. Adult male Wistar rats (300-475 g)
underwent surgery as described by Anidjar et al2 and
modified by Bigatel et al.6 The described protocols were
approved by the Institutional Animal Care and Use
Committee. Animal care complied with the Guide for the
Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council (National Academy
Press, Washington, 1996). The rats were anesthetized
with inhalational isoflurane (1%-2.5%). A laparotomy was
performed, and a 1-cm segment of infrarenal aorta was
isolated. All lumbar artery branches were ligated, and the
Experimental research into the pathophysiology and
treatment of abdominal aortic aneurysms (AAAs) commonly
uses an elastase infusion rat model. This experimental model
has been well described1-4 and induces AAA formation by
infusion of commercially available porcine pancreatic elastase
into the rat aorta. AAAs subsequently develop because of an
inflammatory cascade,5-10 which ultimately results in matrix
destruction by matrix metalloproteinases.
In a number of publications with this model used, the
amount of elastase infused and the sizes of the AAAs pro-
duced have been variable. Initial publications with this
model described formation of AAAs with diameters of 4.4
mm or greater after infusion of 15 units of elastase.2,8
Subsequent investigations have reported AAAs with diam-
eters as small as 2.3 mm by use of the same dose of elas-
tase.9 This has led to the use of higher doses (50 units or
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Purpose: Research investigating abdominal aortic aneurysms (AAAs) commonly uses a rat model dependent on aortic
infusion of porcine pancreatic elastase to initiate AAA formation. Unfortunately, the sizes of AAAs generated by this
model have varied widely among published studies. This may reflect lot-to-lot variations in commercial elastase prepa-
rations. This study was undertaken to investigate the ability of different lots of elastase to induce AAAs and explain
the variability identified. 
Methods: Four lots of elastase were evaluated in the standard rat AAA model. Saline solution was used as a control.
Additional groups of rats were treated with higher concentrations of elastase with or without the macrophage activa-
tor thioglycollate medium. Aortic diameters were measured in all rats. Inflammation and elastin degradation was exam-
ined histologically. Elastase activity and purity were evaluated for all lots. 
Results: Of the four lots tested, only one was able to consistently generate AAAs at the standard dose (P < .05).
Increasing the amount of elastase infused produced AAAs in some ineffective lots. Infusion of thioglycollate medium
in combination with otherwise ineffective elastase produced AAAs (P = .02). However, the elastase with the highest
purity failed to generate AAAs, even at the highest dose tested or in combination with thyioglycollate medium.
Thioglycollate medium alone failed to result in AAA formation. All elastase lots displayed elastolytic activity in vitro
and produced elastin degradation in vivo. Elastin degradation did not correlate with AAA size in elastase-treated rats
(P = NS). Aneurysm size correlated with extent of inflammation (P = .005).
Conclusion: Induction of AAAs does not correlate with elastolytic activity. Infusion of pure elastase alone is not suffi-
cient to induce AAA formation in spite of evidence of elastin degradation. Presumed inflammatory modifiers, which
contaminate some elastase preparations, enhance AAA formation. Future use of this rat model will need to take the
variability of elastase preparations into account with controls for each new elastase lot. (J Vasc Surg 2001;33:1255-62.)
vena cava was dissected free from the aorta. A polyethyl-
ene catheter was threaded into the aorta until its tip was
resting in the isolated segment. Temporary ligatures were
placed proximally and distally, and the aorta was perfused
with either a saline solution control or a commercial elas-
tase preparation dissolved in saline solution. Two milli-
liters was infused over 2 hours with a microinfusion pump. 
Aortic diameter was measured during pulsatile blood
flow both before and after infusion with an ocular microm-
eter. After infusion the catheter was removed and the
femoral artery was ligated. Baseline mean aortic pressure in
three nonrandomized rats was 88 mm Hg. After ligation
the proximal aortic pressure was 41 mm Hg (range, 38-44
mm Hg), which remained constant during the 2-hour
infusion period. The laparotomy was closed, and skin
wounds were stapled. On postoperative day 7 the animals
were anesthetized. The aortas were dissected free, and their
diameters were measured under pulsatile flow as described
above. An aortic aneurysm was defined as an aortic diame-
ter more than twice the preinfusion diameter. The animals
were killed, and the infused segments of aorta were
removed. Tissue was fixed in 3% paraformaldehyde solu-
tion and processed for hematoxylin and eosin staining and
orcein elastin staining. 
Elastase preparations and biochemical characteriza-
tion. Three lots of type I porcine pancreatic elastase (prod-
uct number E-1250) were obtained from Sigma Chemical
Company (St Louis, Mo). Lots tested were 16H8045 (lot
16), 17H8000 (lot 17), and 18H7440 (lot 18). Lots 16, 17,
and 18 from Sigma Chemical Company were manufactured
in sequential order. Highly purified type I porcine pancreatic
elastase (lot 98744, referred to as “lot 98”) was obtained
from ICN Pharmaceuticals, Inc (Costa Mesa, Calif). It
should be noted that starting with lot 17, Sigma Chemical
Company changed the manufacturing techniques and unit
activity definition for elastase. For all activities reported in this
article, one unit of elastase is the amount of enzyme that will
hydrolyze 1.0 µmol/L Succinyl-Ala-Ala-Ala-p-nitroanalide
(SucAla3-pNA) per minute at pH 8.0 at 25°C. One unit of
activity defined in this way is approximately 30 units of elas-
tase defined by the elastin-orcein method, which was used to
assay older lots of Sigma elastase (oral communication, Sigma
technical service, March 11, 1998). Three different elastase
concentrations were tested: standard dose (2 units Sigma
elastase, 4 units ICN elastase), high dose (8 units), and
“mega” dose (12 units). Groups of rats were also infused
with elastase (lot 18) in 3% thioglycollate medium (Sigma
Chemical Company, product number T-9032) in phosphate-
buffered saline solution or thioglycollate medium solution
without elastase. All experimental groups contained five rats
except those infused with lot 16, which contained eight rats.
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Fig 2. Concentration dependence of elastase-generated aneurysm
formation. Isolated segments of aortas from anesthetized rats were
infused with indicated concentrations of Sigma elastase, lot 18, or
more highly purified ICN elastase. Aortic diameters were measured
in situ before infusion (hatched bars) or 7 days after infusion (solid
bars). Bars represent mean ± SEM, n = 5. Dashed line indicates aor-
tic diameter that is two times the mean preinfusion diameter. Only
“mega” dose lot 18 produced aneurysms (P < .0001). More highly
purified ICN elastase failed to produce AAAs, even at “mega” dose. 
Fig 1. Aneurysm-generating activities of commercial elastase
preparations. Isolated segments of aortas from anesthetized rats
were infused with saline solution (sal), or standard doses of four
different commercial preparations of porcine pancreatic elastase.
Elastases 16, 17, and 18 were lots from Sigma Chemical Co.
Elastase 98 was ICN Pharmaceuticals, Inc. Two units (Sigma
preparations) or four units (ICN) of elastase enzyme activity were
infused in a total volume of 2 mL. Aortic diameters were mea-
sured in situ before infusion (hatched bars) or 7 days after infusion
(solid bars). Bars represent mean ± SEM, n = 5 in all groups
except for lot 16, where n = 8. Dashed line indicates aortic diam-
eter that is two times the mean preinfusion diameter. Aortic
diameters in rats infused with lot 16 were significantly greater
than those infused with other elastase preparations (P < .05).
Elastolytic activity was confirmed for all elastase prepa-
rations by use of the SucAla3-pNA assay kit and protocol
from Sigma Chemical Company. Elastase preparations
were examined for contaminating polypeptides by SDS-
gel electrophoresis on 10% polyacrylamide gels. For each
preparation 164 µg was analyzed. Polypeptide bands were
visualized by silver staining. 
Gelatin and casein zymography assays were also per-
formed on each elastase preparation. Each sample of 0.012
units was mixed with nonreducing gel sample buffer and was
loaded onto 10% sodium dodecylsulphate-polyacrylamide
gels from GIBCO-BRL Life Technologies (Gaithersburg,
Md) containing 1 mg/mL of either gelatin or casein. The
gel was washed for 1 hour in a 2.5% Triton X-100 from
Sigma Chemical Co (St Louis, Mo) and rinsed with 
5 mmol/L Tris-HCl, pH 8.0, 5 mmol/L CaCl2 for 30 min-
utes. The gels were incubated at 37°C for 18 hours in 0.05
mol/L Tris-HCl, pH 8.0, 5 µmol/L zinc chloride and then
stained with Coomassie blue.
Quantitation of elastin preservation. Elastin preser-
vation was determined by quantitative morphometric
study. Fixed paraffin-embedded aortas were sectioned in a
transverse plane and subjected to elastin staining. Images of
the stained specimens were captured with a digital camera
attached to a light microscope. The resulting digital images
were pseudocolored, and the inner luminal circumferences
were traced with a mouse-controlled cursor. The circum-
ferential segments that contained intact elastin fibers were
then traced. The lengths of the individual traces (in pixels)
were determined by use of the MetaMorph Imaging soft-
ware (Version 3.5; Universal Imaging Corporation, West
Chester, Pa). Elastin preservation was calculated by divid-
ing the length of elastin-containing segments by the total
circumference. Each measurement was made twice, and the
average values were determined. Quantitation could not be
carried out in four rats because of tissue fragmentation dur-
ing histologic preparation.
Quantitation of inflammation. The severity of
inflammation of elastase-infused aortas was determined by
microscopic inspection of hematoxylin and eosin–stained
paraffin sections. The sections were assigned one of the
following values: 0, no inflammation; 1, slight inflamma-
tion; 2, moderate inflammation; 3, severe inflammation.
All sections were scored by the same investigator, who was
blinded with respect to the treatment and outcome. A
scale was chosen to quantitate inflammation rather than
cell counts per high-powered field because the inflamma-
tory reaction is not symmetric in these samples.
The degree of inflammation in elastase-infused aor-
tas was also estimated by measuring the thickness of the
aortic wall. Transverse sections of paraffin-embedded
aortas were captured with a digital camera attached to a
light microscope. The thickness of the aorta was deter-
mined by measuring the length in pixels of a perpendic-
ular line drawn from the outer vessel surface to the
lumen. Three separate measurements at different loca-
tions around the vessel perimeter were made on each
specimen and averaged. Seven rats were excluded from
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analysis because of tissue fragmentation during histo-
logic processing. 
Statistical analysis. Statistical comparisons among
groups were determined by one-way analysis of variance
with the GraphPAD Software Inc (San Diego, Calif) Instat
program, version 1.14. Linear regression analyses were
carried out with GraphPAD Prizm graphing and analysis
software, version 1.02. 
Fig 3. Thioglycollate medium increases aneurysm size in rats
infused with Sigma elastase but not purified ICN elastase. Top
panel: Isolated segments of aortas from anesthetized rats were
infused with 8 units (high dose) of Sigma elastase, lot 18 (18), 3%
thioglycollate medium (T), or elastase plus thioglycollate medium
(18 + T), as indicated. Bottom panel: Isolated segment of aortas
were infused with 12 units (“mega” dose) of ICN elastase, 3%
thioglycollate medium (T), or elastase plus thyioglycollate
medium (ICN + T). Aortic diameters were measured in situ
before infusion (hatched bars) or 7 days after infusion (solid bars).
Bars represent mean ± SEM, n = 5. Dashed line indicates aortic
diameter that is two times the mean preinfusion diameter.
Administration of thioglycollate medium increased size of AAAs
produced by elastase lot 18 (P = .02). ICN alone or in combina-
tion with thioglycollate medium failed to induce aneurysms. 
RESULTS
Variability of aneurysm-producing potential
among commercial elastase lots. Rat aortas were infused
with four different preparations of porcine pancreatic elas-
tase (three from Sigma Chemical Co, one from ICN
Pharmaceuticals, Inc). Aortas of control rats were infused
with saline solution. As shown in Fig 1, infusion of a stan-
dard dose (2-4 units) of elastase activity per rat produced
an increase in aortic diameter on postoperative day 7. The
elastase preparations varied considerably in the amount of
aortic expansion that they produced. At the standard con-
centration, only one preparation (Sigma lot 16) produced
average aortic diameters that were more than twice the
preinfusion diameters. The mean aortic diameter pro-
duced by lot 16 was significantly greater than those mea-
sured in rats treated with the other elastase lots (P < .05). 
Both Sigma lot 18 and the ICN elastase were ineffec-
tive at producing aneurysms when infused at the standard
concentration (Fig 1). As shown in Fig 2, increasing the
quantity of Sigma lot 18 elastase infused produced signif-
icantly larger aneurysms (P < .0001). At the highest con-
centration tested (“mega” dose), the mean aortic diame-
ters on postoperative day 7 were approximately five times
the mean starting diameters. In contrast to these results,
increasing the dose of ICN elastase to the “mega” dose
failed to produce an increase in aortic diameter. The Sigma
lot 18 and ICN elastase preparations differ in their bio-
chemical purity (see below). These results demonstrate
therefore that infusion of equal amounts of elastase activ-
ity from different lots does not produce a consistent level
of aortic expansion. 
Potentiation of aneurysm-producing activity of
elastase by thioglycollate medium. The findings pre-
sented above suggest that elastase activity alone is not suf-
ficient to generate aneurysms in this experimental model.
An experiment was carried out to determine whether
administration of a proinflammatory substance, thiogly-
collate medium,2 in combination with elastase would
increase the size of the aneurysms produced in the rat
model. As shown in Fig 3, thioglycollate medium alone
failed to produce AAAs. Infusion of Sigma lot 18 elastase
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Fig 4. Elastase degradation in elastase-infused aortas. Representative examples of aortas harvested 7 days after elastase infusion. Paraffin sec-
tions were stained to reveal elastin fibers. Sections were photographed with digital camera and pseudocolored to highlight areas of preserved
elastin (solid black). Note variability in elastin content, from almost complete destruction (A) to essentially complete preservation (C).
plus thioglycollate medium produced aneurysms that were
significantly larger than those produced by infusion of the
same amount of elastase alone (P = .02). Infusion of pure
ICN elastase and thyioglycollate medium failed to pro-
duce aneurysms.
Elastin degradation in infused aortas. Further evi-
dence supporting the conclusion that destruction of elastin
was not sufficient to produce an aneurysm came from an
analysis of the elastin content of elastase-treated rats. Fig 4
shows representative micrographs of aortas infused with
the standard dose of elastase, stained to visualize elastin in
the medial layer of the vessel wall. Considerable variability
in the amount of elastin remaining on postoperative day 7
was apparent. Elastin preservation was measured as
described in the Methods section. Fig 5 shows the rela-
tionship between aortic diameter and elastin preservation
for individual aortas infused with the four different elastase
preparations at the standard or high dose of elastase. Linear
regression analysis failed to demonstrate a significant cor-
relation between aneurysm size and elastin content (r 2 =
.033; slope not significantly different from zero, P = .36). 
Inflammation in elastase-treated aortas. Fig 6
shows representative micrographs of hematoxylin and
eosin stained aortas that were infused with the standard
dose of Sigma lot 16 or ICN elastase. Note the extensive
inflammation in the Sigma elastase–infused aorta and con-
comitant increase in wall thickness caused by inflamma-
tory cell infiltration. In contrast, the ICN elastase–infused
aorta was relatively free of inflammatory cell infiltration.
Inflammation of the aortic wall in elastase-treated rats
was scored by two different methods for all rats infused
with standard and high doses of elastase. Fig 7, A shows
the relationship between aneurysm size and a graded
inflammation index, determined by inspection of hema-
toxylin and eosin–stained paraffin sections. These results
demonstrate a clear correlation between inflammation and
aneurysm size (P = .005). Fig 7, B shows the relationship
between aortic diameter and aortic wall thickness, an indi-
rect measure of inflammation. Linear regression analysis of
these data demonstrated a positive correlation between
aortic diameter and wall thickness (r 2 = .41; significant
non-zero slope, P = .007). 
Biochemical characterization of commercial elastase
lots. The variability in aneurysm-promoting activity among
the commercial elastase preparations tested prompted an
evaluation of their in vitro enzyme activities and purity. All
four commercial lots were assayed for elastolytic activity as
described in the Methods section. All preparations displayed
elastase activity, which ranged from 50% to 200% of the
activities reported by the manufacturers. 
Fig 8, A shows a silver-stained SDS polyacrylamide gel,
which compares the polypeptide compositions of the four
commercial elastase preparations. As expected, the major
band in all of the preparations was the 27-kDa pancreatic
elastase polypeptide. The four preparations displayed a
range of additional contaminating bands. Interestingly, the
most highly purified enzyme, obtained from ICN Pharma-
ceuticals, Inc, was the preparation that produced the small-
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est aortic dilation (see Figs 1 and 2). In contrast, the elas-
tase preparation with the greatest aneurysm formation,
Sigma lot 16, appeared to be the most highly contaminated,
especially in the high molecular weight region of the gel. 
Zymography assays were also used to investigate the
proteolytic activities of the four elastase preparations.
When casein was used as the substrate each of the four
elastase preparations produced zones of clearing, indica-
tive of substrate proteolysis, that corresponded to the
position of migration of the pancreatic elastase polypep-
tide (Fig 8, B). When gelatin was used as the substrate,
each of the elastase preparations displayed gelatinase activ-
ity corresponding to the pancreatic elastase polypeptide.
The Sigma enzyme preparations contained one or more
additional polypeptides with considerable gelatinase activ-
ity. These were demonstrably reduced or lacking in the
ICN preparation (Fig 8,C). 
DISCUSSION
The elastase-induced rat model of AAA disease has
been widely accepted as an appropriate model for studying
the pathophysiology and treatment of AAAs. Until
recently it was assumed that elastase alone was responsible
for the induction of aneurysm formation.2,7 Experiments
from this research project have demonstrated that con-
taminants of commercial elastase preparations are neces-
sary for AAA induction. This is supported by the fact that
rats treated with the most highly purified elastase (from
ICN Pharmaceuticals, Inc) did not have development of
Fig 5. Correlation between aortic diameter and elastin preserva-
tion. Figure compares elastin preservation with aortic diameter in
all rats infused with standard and high doses of elastase. Aortic
diameters were measured in situ 7 days after elastase infusion.
Elastin preservation was measured by morphometric analysis of
tissue sections stained to reveal elastin fibers. Data are expressed
as percent of medial layer diameter that contained visible elastin
staining. Note lack of correlation between aortic diameter and
percent of remaining elastin (P = .36).
any aneurysms, even at “mega” doses or in combination
with thioglycollate medium. 
Interestingly, the elastase preparation most effective at
inducing AAA formation at the standard dose (lot 16) was
found by SDS gel electrophoresis and silver staining to be
significantly contaminated with other polypeptides. SDS
gel electrophoresis and silver staining of the different elas-
tase lots clearly displayed contaminating bands in all Sigma
preparations (Fig 8). Similarly, zymography showed signif-
icant contamination by a gelatinase activity in all Sigma lots
but not in ICN elastase. This gelatinase activity was distinct
from the elastase band. This, however, does not prove that
this particular band is necessary for the initiation of the
inflammatory cascade. There are multiple contaminants in
effective lot 16, and the exact nature of these proteins may
never be elucidated because Sigma has changed the pro-
duction process and this lot is no longer available. 
Results of this study indicate that these contaminants
are most likely inflammatory modifiers that activate the
inflammatory cascade and subsequent AAA formation.
Because the elastase is derived from porcine pancreatic tis-
sue, it is not surprising that these contaminants include
proteins that modify the inflammatory cascade. As demon-
strated by our results, newer Sigma preparations (lots 17
and 18) contain fewer contaminants but unchanged elas-
tolytic activity. These lots failed to produce AAAs when
infused into rat aortas at the standard dose. When one of
these preparations was infused at a “mega” dose,
aneurysms were produced. The inability of these newer
Sigma elastase preparations to produce AAAs was reported
in a letter to the editor.11 These authors also speculated
that protein contaminants in older preparations are neces-
sary for induction of AAAs. 
This unexpected finding has provided additional
insight into the understanding of the development of
AAAs in this rat model. The combination of elastase and a
sufficient quantity of contaminating polypeptides are nec-
essary for the initiation of AAA formation. In the case of
less purified elastase preparations (lot 16) the amount of
contaminating polypeptides is sufficient to induce AAAs
when infused at the standard dose. For more purified
preparations, achieving a sufficient amount of these
polypeptides can be accomplished by infusion of a “mega”
dose of elastase. These results certainly raise the possibility
that elastase by itself is not required in this experimental
model. It is interesting to conjecture that the contami-
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Fig 6. Histologic evaluation of aortic inflammation. Figure shows representative examples of hematoxylin and eosin stained paraffin sec-
tions of aortas infused with standard doses of Sigma lot 16 elastase (left panels) or more highly purified ICN elastase (right panels). Upper
micrographs show low-power views (Original magnification × 10). Note extensive wall thickening produced in aorta infused with Sigma
elastase that is not observed in aorta infused with ICN elastase. Lower micrographs show high-power views (Original magnification ×
40), which reveals abundant cellular infiltration into the aorta infused with Sigma elastase but not aorta infused with ICN elastase. 
nants found in the effective lot 16 may be the initiating
agents. The nature of these contaminants are unknown
but may possess the necessary proteolytic and inflamma-
tory components to initiate the inflammatory process. It
should be noted that infusion of a similar dose of highly
purified elastase fails to induce AAA formation. Thus elas-
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tase-mediated degradation of aortic wall components is
not sufficient to induce AAAs in this model. The lack of
correlation between elastin preservation and aortic diame-
ter (Figs 4 and 5) also supports our contention that elas-
tase itself is not sufficient to induce AAAs. 
The importance of inflammation in AAA formation is
Fig 7. Correlation between aortic diameter and inflammation. A, Aortas of rats that were infused with standard or high doses of elas-
tase were scored for inflammation by microscopic evaluation of hematoxylin and eosin–stained paraffin sections. Each point represents
data for aortic diameter (postoperative day 7) and inflammation of individual elastase-infused aortas. Scale for inflammation ranges from
0 (no inflammation) to 3 (severe inflammation). There is a significant trend of increased inflammation in aortas with larger diameters (P
= .005). B, Elastase-infused aortas were scored for inflammation by measuring aortic wall thickness. Each point represents the data for
aortic diameter (postoperative day 7) and wall thickness of individual elastase-infused aortas. There is significant correlation between wall
thickness and aortic diameter (P = .007).
Fig 8. Gel electrophoresis and zymography analysis of commercial elastase preparations. A, Aliquots of four elastase preparations used
in this study were subjected to electrophoresis on 10% polyacrylamide SDS gels. Polypeptide bands were visualized by silver staining.
Note major pancreatic elastase band migrating slightly ahead of 29-kDa marker, plus variable contaminating bands. B, Aliquots of four
elastase preparations were subjected to zymography assays in 10% polyacrylamide gels that contained protease substrate casein. Light
areas indicate zones of proteolytic activity. C, Aliquots of four elastase preparations were subjected to zymography assays in 10% poly-
acrylamide gels that contained protease substrate gelatin. Light areas indicate zones of proteolytic activity. Note identification of low-
molecular–weight gelatinase activity in Sigma preparations but not in ICN elastase. Numbers to left indicate positions of migration of
molecular weight markers (in kilodaltons).
A B
A B C
underscored by the increased inflammation and aortic wall
thickness observed in rats infused with effective elastase
lots. Increased inflammation and increased aortic wall
thickness were correlated with larger aneurysm size as seen
in Fig 7. Histologically, this is represented in Fig 6 where
a thickened aortic wall is seen in the Sigma-perfused rat
that had development of an AAA. This thickened wall is a
result of the inflammatory response. These findings are
distinctly different from the late stages of human AAAs,
which have a thinned out aortic wall. We have previously
documented these inflammatory cells in the rat model to
be MAC–1α-staining inflammatory cells,6 which include
neutrophils and macrophages.
The addition of thioglycollate medium to an otherwise
ineffective elastase preparation (lot 18) resulted in AAA
formation. These findings are similar to those of Dobrin et
al,10 who were able to create AAAs in this model by com-
bining plasmin with thioglycollate medium. Interestingly,
the combination of highly purified elastase (ICN elatase)
and thioglycollate medium did not initiate aneurysm devel-
opment. This suggests that inflammatory modifiers found
in the Sigma elastase are necessary to initiate the aneurys-
mal process in the rat. 
One issue that might cause some confusion is the
change in the substrate used to assay elastolytic activity
and elastase unit definition utilized by commercial ven-
dors. One unit of SucAla3-pNA activity is approximately
30 units as measured by the older elastin-orcein assay.
Earlier studies that used 15 or 50 units of orcein-elastase
activity would be equivalent to using 0.5 or 1.7 units of
SucAla3-pNA activity. The standard dose (2 units of
Sigma elastase on the basis of the newer assay) used in this
study corresponds to approximately 60 units of elastin-
orcein activity. Our “mega” dose (12 units) corresponds
to approximately 360 units of elastin-orcein activity. In a
recent study from another laboratory 14 units of elastase,
(equivalent to 420 of the older elastin-orcein units) was
shown to produce large AAAs in the rat model.12 These
investigators reported a high mortality rate with standard
infusion times because of the high dose of elastase used.
Decreasing the infusion time diminished mortality rates in
the rats. The findings presented here demonstrate that
induction of AAAs in the rat model does not correlate
with elastase activity and that elastase alone is not suffi-
cient to induce AAA formation. Because of the variability
in AAA formation by different elastase preparations, it will
be critical for future reports to indicate the elastase lot
used and have appropriate control groups to document
the ability of the preparation to induce AAAs.
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